Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED E-Z-PASTE ® is supplied in the following quantity: 454 g Tube, Cat. No. 770; NDC 32909-770-01 Manufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc. a subsidiary of Bracco Diagnostics Inc. Monroe Township, NJ 08831 Tel: 1-516-333-8230 1-800 544-4624 rev. 10/17 CL80E01 TX1887; E-Z-Paste - Barium Sulfate Esophageal Cream NDC: 32909-770-01 CL80E02 rev. 01/2023 E-Z-Paste Tube; E-Z-Paste - Carton E-Z-Paste Carton
- HOW SUPPLIED E-Z-PASTE ® is supplied in the following quantity: 454 g Tube, Cat. No. 770; NDC 32909-770-01 Manufactured by E-Z-EM Canada Inc. for E-Z-EM, Inc. a subsidiary of Bracco Diagnostics Inc. Monroe Township, NJ 08831 Tel: 1-516-333-8230 1-800 544-4624 rev. 10/17 CL80E01 TX1887
- E-Z-Paste - Barium Sulfate Esophageal Cream NDC: 32909-770-01 CL80E02 rev. 01/2023 E-Z-Paste Tube
- E-Z-Paste - Carton E-Z-Paste Carton
Overview
E-Z-PASTE ® Barium Sulfate Esophageal Cream (60% w/w) is a barium sulfate cream for oral administration. Each 100 g contains 60 g barium sulfate. Barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. The active ingredient is barium sulfate and its structural formula is BaSO 4 . Barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. Its aqueous suspensions are neutral to litmus. It is practically insoluble in water, solutions of acids and alkalies, and organic solvents. Inactive Ingredients: carboxymethylcellulose sodium, citric acid, ethyl vanillin, glycerin, methylparaben, propylparaben, purified water, saccharin sodium, simethicone emulsion, sodium citrate, and sorbitol solution.
Indications & Usage
For use in single contrast radiography of the esophagus, pharynx, hypopharynx and for cardiac series.
Dosage & Administration
Usual dose is one to four teaspoons as required.
Warnings & Precautions
WARNINGS Rarely, severe allergic reactions of an anaphylactoid nature, have been reported following administration of barium sulfate contrast agents. Appropriately trained personnel and facilities should be available for emergency treatment of severe reactions and should remain available for at least 30 to 60 minutes following administration, since delayed reactions can occur.
Contraindications
This product should not be used in patients with known gastric or intestinal perforation or hypersensitivity to barium sulfate products.
Adverse Reactions
Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium sulfate impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. It is of the utmost importance to be completely prepared to treat any such occurrence.
Drug Interactions
The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.
Storage & Handling
Storage Store product at USP Controlled Room Temperature, 20 to 25°C (68 to 77°F). Protect from freezing.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.